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Targeting Mesothelioma Using an Infectivity Enhanced
Survivin-Conditionally Replicative Adenoviruses
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Shuyi Wang, MD,‡ Koichi Takayama, MD,§ Gene P. Siegal, MD, PhD, Paul N. Reynolds, MD,¶
and David T. Curiel, MD, PhD*
Mesothelioma is a highly malignant neoplasm with no effective
treatment. Conditionally replicative adenoviruses (CRAds) rep-
resent a promising new modality for the treatment of cancer in
general. A key contribution in this regard is the introduction of
tumor-selective viral replication for amplification of the initial
inoculum in the neoplastic cell population. Under ideal condi-
tions following cellular infection, the viruses replicate selectively
in the infected tumor cells and kill the cells by cytolysis, leaving
normal cells unaffected. However, to date there have been two
limitations to clinical application of these CRAd agents; viral
infectivity and tumor specificity have been poor. Herein we
report on two CRAd agents, CRAd-S.RGD and CRAd-S.F5/3, in
which the tumor specificity is regulated by a tumor-specific
promoter, the survivin promoter, and the viral infectivity is
enhanced by incorporating a capsid modification (RGD or F5/3)
in the adenovirus fiber region. These CRAd agents effectively
target human mesothelioma cell lines, induce strong cytoxicity in
these cells in vitro, and viral replication in a H226 murine
xenograft model in vivo. In addition, the survivin promoter has
extremely low activity both in the non-transformed cell line,
HMEC, and in human liver tissue. Our results suggest that the
survivin-based CRAds are promising agents for targeting me-
sothelioma with low host toxicity. These agents should provide
important insights into the identification of novel therapeutic
strategies for mesothelioma.
Key Words: Survivin gene, Tumor-specific promoter, Transcrip-
tional targeting, Adenoviral vector and mesothelioma.
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Mesotheliomas are neoplasms of the serosal membranesof body cavities, arising principally from the pleura,
peritoneum, and tunica vaginalis. Eighty percent of mesothe-
liomas involve the pleural space, and they represent the most
common primary tumor of the pleural cavity. Despite its
relative rarity in the United States, mesothelioma remains an
area of special interest in pulmonary medicine because of its
increasing frequency, dismal prognosis, and attendant medi-
colegal issues related to asbestos exposure. Mesotheliomas
are classified into three general categories: diffuse malignant,
localized benign, and localized malignant. Ten percent of
localized mesotheliomas are malignant, but they are often
low-grade and potentially resectable.1,2 Diffuse pleural me-
sothelioma account for the preponderance of primary pleural
tumors. No particular therapy has proven reliably superior to
supportive therapy alone in terms of survival. The median
survival for patients without treatment is 6 to 8 months, quite
similar to the survival for those who received therapy, in-
cluding chemo- or radiotherapy and surgery.3–12 There is no
widely accepted newer treatment strategy for patients with
pleural mesothelioma. To that end, a novel therapeutic ap-
proach to pleural mesothelioma is warranted.
Gene therapy has shown potential for the treatment of
other solid cancers. In a recent summary of gene therapy
clinical trials worldwide (1989 to 2004), 66% of such trials
addressed cancers.13 Strategies for anti-mesothelioma thera-
pies by gene therapy include: (1) molecular chemotherapy
based on the use of “suicide genes,” such as the herpes
simplex thymidine kinase gene14,15 and cytosine deaminase,16
in which DNA that encodes an enzyme capable of generating
a toxic metabolite is transferred to tumor cells followed by
the administration of a nontoxic enzyme substrate; (2) genetic
immunopotentiation based on the capacity to destroy tumor
cells either via T lymphocytes, natural killer cells, or macro-
phages17 or by use of immunomodulators, such as IL-218 and
TGF-19; (3) mutation compensation based on correction of
oncogenes or tumor-suppresser genes, such as K-ras, p53,
P16 INK4A, P14, and NF2 genes.20–24 Thus, in this regard, a
number of gene therapy approaches for mesothelioma have
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been developed. Furthermore, gene therapy of mesothelioma
may be useful in combination with conventional therapies.
Recently, the use of replicative viral delivery represents
a novel approach to such neoplastic diseases, including ma-
lignant mesothelioma.25 In this strategy, target tumor cell
killing by the viral agent is achieved via direct consequence
of the viral replication.26 It is apparent that the specificity of
the viral agent for achieving tumor cell killing via replication
(“oncolysis”) is the functional key to successful exploitation
of these agents. To this end, an ideal viral agent would
possess two characteristics: (1) high infectivity, in that viral
vectors would have the capacity to infect tumor versus
non-tumor cells; and (2) tumor specificity, in that viral vec-
tors would possess a relative preference for replication in
tumor versus non-tumor cells. However, both viral infectivity
and specificity have been poor when using current applicable
conditionally replicative viral vectors (CRAds). To develop
infectivity enhanced and tumor-specific CRAd agents for
mesotheliomas, better constructs are needed.
To overcome these two disadvantages of poor infectiv-
ity and specificity, many approaches have been described.
Important in the consideration of efficient infection is the
knowledge that cells may be resistant to Ad infection because
of their lack of the Coxsackie adenovirus receptor (CAR) on
their cell surfaces that result in poor infectivity.27 To circum-
vent this, genetic and immunologic alterations to the virus
fiber that use CAR-independent pathways have been identi-
fied. An example of this is the use of the RGD motif in the
fiber knob of the Ad. This capsid modification seems to
facilitate Ad binding and entry into tumor cells via integrin
receptors that are abundantly expressed on many solid tumor
cells.27 Additional capsid modifications have been explored
to obtain infectivity enhancement of Ads, including AdF5/
3,28Ad5-pk7,29 and Ad5-CK.30 Alternately, transcriptional
targeting exploits promoters that display preferentially in
tumor cells but not in normal host cells.26 An ideal tumor-
specific promoter (TSP) for transcriptional targeting exhibits
selective high activity in tumor cells (termed a “tumor on”
phenotype). To mitigate hepatoxicity on systemic delivery,
candidate promoters additionally exhibit low activity in the
liver (termed a “liver off” phenotype). To develop TSP-
CRAds, one of the most widely used methods is to drive Ad
E1 gene expression with a selected promoter, as Ad E1 is the
main element that drives viral replication. In this method, a
CRAd replicates only in tumor cells, killing cells by oncol-
ysis, but not in normal host cells, thereby avoiding the
toxicity of the CRAd agent. Many TSPs have been explored
for specific cancers, such as the prostate-specific antigen
(PSA) for prostate cancer and the -fetoprotein (AFP) pro-
moter for hepatocarcinoma.31,32 Recently we reported a novel
TSP, the survivin promoter, which exhibited a tumor on/liver
off phenotype in vitro and in vivo in a wide range of
neoplastic tumors.33 This promoter has also been reported to
exhibit a radiation-responsive promoter and cisplatin-sensi-
tive capabilities.34,35 Therefore, the survivin promoter is an
excellent candidate to drive E1 expression in the development
of a new CRAd agent.
In this study, we further constructed conditionally rep-
licative adenoviral vectors, in which the Ad E1 gene was
regulated by using the survivin promoter as a TSP and viral
infectivity was enhanced with a capsid modification (RGD or
F5/3) by which Ad vector target to mesothelioma cells
occurred via a CAR-independent pathway. We verified that
these infectivity enhanced and tumor-selected vectors, espe-
cially CRAD-S.F5/3, replicated in mesothelioma cells and in
a H226 xenograft murine model. We also showed that the
survivin promoter had very low activity compared with the
other TSPs in human liver slices. Our data thus indicate that
the CRAd-S.F5/3 is an excellent candidate for translation into
a clinical trial for the treatment of malignant mesothelioma in
humans.
MATERIALS AND METHODS
Cells, Tissues, and Animals
Human mesothelioma cell lines, H226 (purchased from
ATCC), H 2373, mmp4, and BC286-2b (gifts from Dr. J.
Kolls, Pittsburgh, PA) were used in this study. All cells were
cultured in RPMI 1640 complete medium supplemented with
10% fetal calf serum, penicillin (100 IU/ml), and streptomy-
cin (100 g/ml). Cells were incubated at 37°C in a 5% CO2
environment under humidified conditions. Non-transformed
human mammary epithelial cells (HMEC), used as a survivin
expression-negative control, were purchased from Cambrex
BioScience Company (Walkersville, MD) and cultured in the
medium specially purchased from the same company.
Human liver samples were obtained from hepatectomy
remnants not needed for diagnostic purpose after liver trans-
plantation after institutional review board approval. To gen-
erate liver tissue slices, tissue was cut in consecutive 0.5-mm
slices using the Krumdieck tissue slicer (Alabama Research
Development, Munford, AL). Sequential slices were then
cultured in 24-well plates in RPMI supplemented with 10%
bovine fetal serum, 100 U/ml penicillin, 100 g/ml strepto-
mycin, and 5 g/ml insulin. Cultures were maintained at
37°C in a humidified atmosphere of 95% air and 5% CO2.
Three tissue slices were examined per group.
Female BALB/c nude mice, 6 to 8 weeks of age
(Charles River, Wilmington, MA), were used for in vivo
experiments. All animals received humane care based on the
guidelines set by the American Veterinary Association. All of
the experimental protocols involving live animals were re-
viewed and approved by the institutional Animal Care and
Use Committee of the University of Alabama at Birmingham.
Recombinant Adenoviruses
Ad5-CMV, Ad5-Cox-2, Ad5-CXCR4, Ad5-EGP-2,
Ad5-HPR, Ad5-SLPI, Ad5-MsLn, and Ad5-Survivin are rep-
licative-defective Ads containing a luciferase reporter gene
driven by the TSP—Cox-2, CXCR4, EGP-2, HPR, SLPI,
MsLn, surviving, and a control CMV promoter, respective-
ly—in the E1 region, as has been previously described.33,36–40
These Ads were used in this study for evaluating the tran-
scriptional activities of the TSPs by means of the expression
of a luciferase reporter gene in mesothelioma cells.
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Ad5.RGD, Ad5.pk7, Ad5.F5/3, Ad.CK and
Ad5.pk7.RGD are replicative-defective Ads containing a lu-
ciferase reporter gene driven by the CMV promoter in the E1
region and incorporating a capsid modification, RGD, pk7,
F5/3, Ad.CN, and pk7.RGD, respectively, as described pre-
viously.28–30 These Ads also were used for evaluating the
enhancement of viral infectivity by means of the expression
of a luciferase reporter gene in mesothelioma cells.
All the Ads used are listed in Table 1. The viruses are
all isogenic, propagated in 293 cells, and purified by double
CsCl density centrifugation. The firefly luciferase gene incor-
porated into the Ads contains a modified coding region for
firefly luciferase (pGL3; Promega) that has been optimized
for monitoring transcriptional activity in transfected eukary-
otic cells. The luciferase activity of the cells infected with
each of Ads was normalized and reported as fold-activity of
cells infected with Ad5.CMV.
Physical particle concentration (vp/ml) was determined
by OD 260 nm reading. All experiments were based on vp
numbers, although a plaque assay was performed to ensure
sufficient quality of the virus preparation. The ratios of vp/pfu
(plaque forming units) were 3.9 to 60 among all Ad vectors
tested.
Real-Time Polymerase Chain Reaction for
Detection of the Expression of the Survivin
Gene, the Ad5 E1 Gene, and the E4 Gene
For survivin gene expression determinations, total cel-
lular RNA was extracted from 5  105 mesothelioma cells
(H226, H2373, Meso MMp4, and Meso BL286-2b) or from
the non-transformed normal control, HMEC, by using the
RNeasy Mini kit (Qiagen, Valencia, CA), followed by treat-
ment with DNase to remove any possible contaminating
DNA from the RNA samples. The fluorescent TaqMan probe
(6FAM-TGACGACCCCATAGAGGAACATAAAAAGCAT)
and the primer pair (forward primer TGGAAGGCTGG-
GAGCCA; reverse primer GAAAGCGCAACCGGACG)
used for real-time PCR in the analysis of the survivin mRNA
were designed using Primer Express 1.0 (Perkin Elmer,
Foster City, CA) and synthesized by Applied Biosystems
(Foster City, CA). Glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was used as the internal control. A negative
control with no template was performed for each reaction
series. RT-PCR reaction was performed using a LightCycler
System (Roche Molecular Biochemicals, Indianapolis, IN).
Thermal cycling conditions were subjected to 2 min at 50°C,
30 min at 60°C, 5 min at 95°C, then 40 cycles of 20 seconds
at 94°C and 1 min at 62°C. Data were analyzed with Light
Cycler software.
For quantification of the Ad E1 and E4 gene, total
cellular RNA or DNA was extracted from cells or cell
cultures in 12/24 well plates using the RNeasy mini RNA
extraction kit or a blood DNA kit (Qiagen), respectively.
Both RNA and DNA samples were treated with RNase-free
DNase and DNase-free RNase, respectively, to remove pos-
sible contamination. The Ad5 E1 gene was detected in RNA
samples by using an oligo pair (forward primer-5=AAC-
CAGTTGCCGTGAGAGTTG and reverse primer-5=CT-
DGTTAAGCAAGTCCTCG ATACA) and the probe (ORF6-
CACAGCTGGCGACGCCCA); the Ad5 E4 gene was
detected in DNA samples by using an oligo pair (forward
primer-5=GGAGTGCGCCGAGACAAC and reverse primer-
5=ACTACGTC CGGCGTTCCAT) and the probe (ORF6-
TGGCATGACACTACGACCAACACGATCT).
Negative controls and an internal control were per-
formed for each reaction series as described.
Transcriptional and Transductional Evaluations
In Vitro
Mesothelioma cells (5  104 cells/well) were plated on
24-well plates in 1 ml of medium as described previously.
The next day, cells were infected with recombinant Ads
TABLE 1. Characteristics of Adenoviral Vectors Used in this Study
Virus name Promoter Reporter E1 E3 Modification Replication competent
Ad5-CMV CMV Luciferase No No No No
Ad5-Cox-2 Cox-2 Luciferase No No No No
Ad5-CXCR4 CXCR4 Luciferase No No No No
Ad5-EGP-2 EGP-2 Luciferase No No No No
Ad5-HPR HPR Luciferase No No No No
Ad5-SLPI SLPI Luciferase No No No No
Ad5-Mk Midkine Luciferase No No No No
Ad5-Survivin (Ad5-S) Survivin (S) Luciferase No No No No
Ad5.RGD CMV Luciferase No No RGD4C No
Ad5.F5/3 CMV Luciferase No No F5/3 No
Ad5.pk7 CMV Luciferase No No pk7 No
Ad5.CN CMV Luciferase No No CN (canine knob) No
Ad5.CN.pk7 CMV Luciferase No No CN.pk7 No
Adwt Native No Yes Yes No Yes
CRAd-S.RGD Survivin (S) No Yes Yes RGD4C Yes
CRAd-S.F5/3 Survivin (S) No Yes Yes F5/3 Yes
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(Ad5-CMV, Ad5-Cox-2, Ad5-CXCR4, Ad5-EGP-2, Ad5-
HPR, Ad5-SLPI, Ad5-MsLn, and Ad5-Survivin for transcrip-
tion or Ad5.RGD, Ad5pk7, Ad5F5/3, and Ad5pk7.RG for
transduction) at 100 vp/cell for 2 hours in 200 l of the
medium containing 2% fetal calf serum (FCS). The cells were
then washed once with 1 ml of phosphate-buffered saline
(PBS), and 1 ml of the medium containing 10% FCS was
added to each well. After 48 hours’ incubation, cells were
washed with PBS, and luciferase activity was determined
using the Reporter Lysis Buffer and Luciferase Assay System
of Promega (Madison, WI) following the manufacturer’s
protocol. Experiments were performed in triplicate, and lu-
ciferase activities were standardized to relative light units
(RLU) values of the CMV promoter (the CMV promoter
activity being set to 100%). The transcriptional levels of the
TSP in mesothelioma cells were evaluated by expression
activity of the luciferase reporter gene in Ads under the
control of these different TSPs. The transductional levels of
Ads in mesothelioma cells were evaluated by the expression
activity of the luciferase reporter gene driven by the same
CMV promoter but incorporating a different capsid modifi-
cation in the Ad fiber region.
Development of CRAd Agents
The CRAd genomes were constructed via homologous
recombination in Escherichia coli (Fig. 1) as described pre-
viously.26 Briefly, DNA fragments containing nucleotides
230/30 were cut with Bam HI and Hind III restriction
endonucleases from the clone pLuc-cyc1.2 (from Dr. F. Li,
Buffalo, NY) and subcloned into the plasmid pBSSK (Strat-
agene, La Jolla, CA) using the same restriction sites. A SV40
poly-A (PA) fragment was then cut with Xba I/Bam HI from
a pGL3B vector (Invitrogen, Carlsbad, CA) and inserted into
the pBSSK using the same restriction sites. A generated clone
named pBSSK/PA/Survivin was used to create shuttle vec-
tors. DNA fragments containing SV40 PA and survivin
promoter were cut with Not I/Xho I and subcloned into a
pScsE1 plasmid, which was a gift from Dr. D. Nettelbeck
(Erlangen, Germany). It contains the E1 gene with the same
restriction sites. The shuttle vectors pScs/PA/S were thus
generated.
The Ad vector, pVK503c,25 was a kind gift from Dr. V.
Krasnykh (M.D. Anderson, Houston, TX), and contains both
the E3 gene and a capsid-modified RGD. After cleavage with
Pme I, the shuttle vectors were recombined with Cla I
linerized pVK503c to generate a CRAd genome with a
RGD-modified fiber. The resultant plasmids encoding the
surviving-promoter CRAds were linearized with Pac I and
transfected into 911 cells using superfect (Qiagen). Generated
viruses were propagated in D65 cells (a glioma cell line in
which survivin gene is over-expressed) and purified by dou-
ble CsCl density gradient centrifugation, followed by dialysis
against PBS containing 10% glycerol. The viruses, CRAd-
S.RGD, were titrated by a plaque assay, and vp number was
determined spectrophotometrically based on absorbance at a
wavelength of 260 nm. The viruses were stored at -80°C until
use. The CRAd-S.F5/3 was generated by a similar method
except that the Ad vectors pVK500F5/3,28 which contained a
F5/3 capsid modification, were already stored in our labora-
tory. Wild-type Ad5 (Adwt) and Ad5.Survivin33 were used as
replication-positive and -negative controls, respectively, in
the CRAd agent analysis.
Analysis of Transduction of CRAd Agents in
Tumor Cell Lines
Mesothelioma cells (1  105/well) were cultured as
discussed, infected with 100 vp/cell Ad-S, CRAd-S.RGD,
CRAd-S.F5/3, or Adwt in infection medium containing 2%
FBS, and incubated at 37°C in a 5% CO2 environment. After
3-hour incubation, the infection medium was removed, and
the cells were washed three times to remove un-internalized
viruses. DNA was isolated from cells derived from each well
via the DNeasy Tissue Kit (Qiagen), and quantitative reverse
transcriptase-polymerase chain reaction (RT-PCR) was per-
formed. Ad E4 gene copy numbers were detected and nor-
malized to the human actin gene.
Analysis of Replication of CRAd Agents in
Tumor Cells
Mesothelioma cells (1  105/well) were cultured as
discussed, infected with 100 vp/cell Ad-S, CRAd-S.RGD,
CRAd-S.F5/3, or Adwt in infection medium containing 2%
FBS, and incubated at 37°C in a 5% CO2 environment. After
3-hour incubation, infection medium was removed, the cells
were washed three times to remove un-internalized viruses,
and cells were placed in fresh culture medium with 10% FBS.
FIGURE 1. Construction of the CRAd agents. A 260 bp of the survivin promoter was amplified from the clone pLuc-cyc1.2
and constructed in a pScE1 vector. A poly-A signal sequence was inserted between the ITR and Survivin promoter to termi-
nate the transcription signal from the ITR. Constructed clones were recombinated with pVK503C or AdF5/3 vector which con-
tain the E3 gene and a RGD4C or F5/3 fiber motif to generate the CRAd-S.RGD and CRAd-S.F5/3, respectively. Both capsid
modifications are located in the region of the Ad fiber.
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Media from triplicate wells were collected 1, 3, and 9 days
later, and DNA was extracted from 200 l of media with the
DNeasy Tissue Kit (Qiagen). Quantitative RT-PCR was per-
formed as described above. Ad E4 gene copy numbers were
detected.
In Vitro Analysis of Cytocidal Effects
The in vitro cytocidal effects of the CRAd agents were
analyzed by determining the viability of the cells with crystal
violet staining after infection. Briefly, 25,000 mesothelioma
cells/well were plated on a 24-well plate; cells were infected
at 500, 100, 20, 4, 0.8, and 0 vp/cell with Adwt, CRAd-
S.F5/3, CRAd-S.RGD, or reAd-S in infection medium, re-
spectively. Two hours later, the infection medium was re-
placed with the appropriate complete medium. After 10-day
incubation, the cells were fixed with 10% buffered formalin
for 10 minutes and stained with 1% crystal violet in 70%
ethanol for 20 minutes, followed by washing three times with
tap water and air drying. Trypan blue exclusion experiments
were also performed as described elsewhere.
Replication of CRAd Agents on a H226 Murine
Xenograft Model
The H226 tumor cells were verified to have 95%
viability by Trypan blue exclusion. BALB/c nude mice were
subcutaneously inoculated in their flanks with 5 106 viable
H226 cells (n  5 per group). When the tumor reached 5 mm
in widest diameter, 5  108 vp of each viral vector (Adwt,
Ad-S, CRAd-S.RGD, or CRAd-S.F5/3) were injected intra-
tumorally. The mice were killed on day 1 or day 7, and the
tumor samples were harvested. The DNA was isolated from
the tumor samples as described previously. DNA samples
from xenografts were stored at -80° C until use. E4 gene copy
numbers were detected by RT-PCR and normalized against
the human actin gene.
Analysis of Promoter and Transductional
Activities in Human Liver Slices
Human liver was obtained from hepatectomy speci-
mens after liver transplantation for evaluation of TSP activ-
ity. To generate liver tissue slices, tissue was cut in consec-
utive 0.5-mm slices using the Krumdieck tissue slicer.
Sequential slices were then cultured in 24-well plates in
RPMI supplemented with 10% FBS, 100 U/ml penicillin, 100
g/ml streptomycin, and 5 g/ml insulin. The tissue slices
were infected with 500 vp/cell of Ad vector, Ad5-CMV,
Ad5-Cox-2, Ad5-CXCR4, Ad5-EGF-2, Ad5-MsLn, Ad5-
SLIP, or Ad5-Survivin with infection medium, respectively.
After 3-hour infection, the liver slices were washed once with
PBS, and 10% FBS was added for 48-hour incubation at 37°C
in a humidified atmosphere of 95% air and 5% CO2. Two
days after infection, luciferase activities were detected by
conventional means and shown as RLU % (relative light
units) of the luciferase activity of the CMV promoter.
Similar experiments were performed for transductional
activity, except the vectors used were Ad5-CMV, Ad5.pk7,
Ad5.F5/3, Ad5.RGD, Ad5.CN, and Ad5.CN.pk7, respec-
tively.
Statistical Analysis
We used Student’s t test for statistical analysis, in
which p  0.05 was considered to be statistically significant.
RESULTS
Evaluation of Tumor-Specific Promoters In
Vitro
The activities of seven TSPs (the Cox-2, CXCR4,
EGP-2, HPR, SLPI, MsLn, and survivin promoters) were
evaluated in four human mesothelioma cell lines: H226,
mmp4, H2373, and BC286-2b. The backbone structure of the
Ad vectors was identical for all constructs, which additionally
contained a luciferase reporter gene derived from a pGL3
plasmid (Promega) that specifically drove luciferase gene
expression. The activities of the Ad vectors in tumor cells
were normalized to an Ad5-CMV vector that had identical
backbone but used the CMV promoter. The results are shown
in Figure 2, A and B. Three of the seven TSPs (the survivin,
CXCR4, and MsLn promoters) exhibited higher promoter
activity than the other TSPs in the mesothelioma cell lines.
The mean activities for the four cell lines were 8.9 % for the
survivin promoter, 4.2 % for the CXCR4 promoter, and 3.3 %
for the MsLn promoter compared with that of the CMV
promoter. The mean activities of the remaining promoters
were less than 2% in these same cell lines. These data show
that these three promoters have a tumor-on phenotype. In
addition, the survivin gene expression was 105 copies/ng
RNA (SD7.8) in H226 cells, 55 copies/ng RNA (SD4.2)
in H2372 cells, and undetectable (0) level in survivin expres-
sion-negative cell line, HMEC, as detected by RT-PCR (sig-
nificant difference, p  0.01) (Fig. 2 C). All of the survivin
transcription levels in the different cell line were normalized
to that of the housekeeping gene, GAPDH.
Evaluation of Capsid Modification In Vitro
Six capsid modifications, the pk7, pk7.RGD, RGD,
F5/3, CN1, and CN.pk7, were generated for viral infectivity
enhancement via a CAR-independent pathway, as described
previously. All the Ad vectors had a similar backbone, as
described, the difference being the incorporation of alterna-
tive modifications in the Ad fiber region (Figure 3). The
activities of the modified Ad vectors in the mesothelioma
tumor cells were normalized to an Ad5-CMV vector that had
the same backbone as the native Ad5 fiber. The data are
shown in Figure 3. The Ad vector with the F5/3 modification
exhibited the highest reporter activities among the four me-
sothelioma cell lines tested. They were 184%, 585%, 449%,
and 535% in H2373, Meso BC2862b, H226, and MesoMMP4
cell lines, respectively, compared with that of the Ad5-CMV
with native fiber. These data show that the F5/3 capsid
modifications should be excellent candidates for viral infec-
tivity enhancement in mesothelioma-directed CRAd agents.
Transcriptional and Transductional Activities of
Modified Ads in Human Liver Slices
Because Ad replication is species-specific and because
the major Ad toxicity in gene therapy trials is hepatic, we
tested six TSPs and one positive control, the CMV promoter,
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for activities in human liver specimens in organ culture. To
indirectly evaluate viral replication under the control of the
selected TSP, we measured luciferase expression after a
2-day infection period with Ad5-CMV, Ad5-Cox-2, Ad5-
CXCR4, Ad5-EGP-2, Ad5-HPR, Ad5-SLPI, Ad5-MsLn, and
Ad5-Survivin (Figure 4A). Compared with the CMV pro-
moter, the survivin promoter activity was the lowest (1.2% of
the activity of the CMV promoter) among the six TSPs. In
other words, the activity of the CMV promoter was 83-fold
higher than that of the survivin promoter in human liver
slices. These data suggest that the survivin promoter has a
liver-off phenotype that should result in low toxicity to the
human host’s liver.
We also compared the transductional activities of four
capsid modified Ad in human liver slices (Figure 4B). The
experiments were performed as previously described, except
that Ad5-CMV, Ad5.pk7, Ad5.F5/3, Ad5.RGD, Ad5.CN, and
Ad5CN.pk7 were used in this experiment. The luciferase
expression level served as a surrogate for the Ad transduc-
tional activity because the luciferase reporter gene was reg-
ulated by the same CMV promoter in all four Ad vectors.
Among these Ad vectors, only the pk7 modification exhibited
lower (2.6%) transduction activity compared with the CMV
promoter in the human liver slices. The transductional activ-
ities of the F5/3 modification (RLU 379,297  160,297) and
RGD (RLU 322,405123,050) were 2.3-fold and 2.0-fold
higher than that of the CMV promoter (RLU  160,893 
24983), respectively, in human liver slices.
FIGURE 2. (A) Comparison of promoter
activities in mesothelioma cells. 5  104
cells mesothelioma cells (H226, mmp4,
H2373, and BC286-2b) were plated on 24-
well plates and infected at a MOI of 100
vp/cell with Ad5-CMV, Ad5-Cox-2, Ad5-
CXCR4, Ad5-EGP-2, Ad5-HPR, Ad5-SLPI,
Ad5-MsLn, or Ad5-Survivin, respectively. Lu-
ciferase activities were analyzed 48 hours
later. Results are shown as relative light
units (RLU) of luciferase activity. (B) RLU of
promoter activities in mesothelioma cells.
The percentage of luciferase activity  (RLU
induced by TSP)/(RLU induced by the CMC
promoter)  100%. The mean value of four
mesothioma cell lines (H226, mmp4,
H2373, and BC286-2b)  SD of triplicate
samples is shown. (C) Survivin and GAPDH
gene expression in mesothelioma cell lines
and HMEC cells, as a survivin expression-
negative control. Both mesothelioma and
HMEC cells (5  104 cells) were plated on
24-well plates. After 48-hour incubation, the
RNA was isolated from cells, and both sur-
vivin and GAPDH RNA copy numbers were
determined by using RT-PCR. The mean
value  SD of triplicate samples is shown.
**p  0.01.
FIGURE 3. Comparison of transductional activity in me-
sothelioma cells with different capsid-modified adenovirus
vectors. The mesothelioma cells (5  104 cells) were plated
on 24-well plates and infected at a MOI of 100 vp/cell
Ad5-CMV, Ad5.pk7, Ad5.RGD, Ad5.F5/3, Ad5.CN, or
Ad5.CN.pk7, and luciferase activities were analyzed 48 hours
later. Results are shown as relative light units (RLU) of lucif-
erase activity. The percentage of luciferase activity  (RLU
induced by TSP)/(RLU induced by the CMC promoter) 
100%. The mean value  SD of triplicate samples is shown.
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Transductional Activities of Capsid-Modified
CRAds in Mesothelioma Cells
Most human tumors contain only low levels of the
CAR, the natural endogenous receptor for human adenovirus
serotypes 2 and 5. We have previously shown that capsid
modification enhances viral infectivity via a CAR-indepen-
dent pathway. In this study, we compared two capsid modi-
fications, which were incorporated into the fiber region in the
CRAd agents and tested in the mesothelioma cell lines H226
and H2373. To avoid viral replication, we infected tumor
cells for only 3 hours and immediately isolated DNA from
them. We had previously developed evidence that 18 to 24
hours were required to detect Ad DNA in medium, which
corresponds to the life cycle of Ad from its entry into the
tumor cells to its release from them. The adenoviral copy
number was determined by real-time PCR and normalized to
the housekeeping gene, actin. The data are shown in Figure 5
A and B. We compared the transductional levels (including
viral binding and internalization) of two CRAd agents carry-
ing different capsid modification, the RGD and F5/3, in H226
and H2373 tumor cells. The results indicate that the CRAd-
S.F5/3 enhanced the transduction between 2.5- and 3.3-fold
in H226 cells and between 1.9- and 3.5-fold in H2373 cells,
compared with non-modified Ad, Adwt, and Ad-S at a MOI
of 1000 vp/cell. The CRAd-S.RGD enhanced the transduc-
tion between 1.6- and 2.2-fold in H226 cells and between 1.3-
and 2.4-fold in H2373 cells, compared with non-modified Ad,
Adwt, and Ad-S at a MOI of 1000 vp/cell. There are signif-
icant differences in CRAd-S.F5/3 compared with Ad-S and
Adwt (p  0.01 in two tested cell lines): CRAd-S.RGD
compared with Ad-S (p  0.01 in both cell lines) and with
Adwt (p  0.05) in the H226 cell line, but not in the H2373
FIGURE 4. Transcriptional (A) and trans-
ductional (B) activity of Ad vectors in human
liver slices. Human liver slices were infected
with 500 vp/cell Ad vector, Ad5-CMV, Ad5-
Cox-2, Ad5-CXCR4, Ad5-EGPF-2, Ad5-MsLn,
Ad5-SLIP, or Ad5-Survivin A and Ad5-CMV,
Ad5.pk7, Ad5.F5/3, Ad5.RGD, Ad5.CN1,
or Ad5.CN2 B . Two days after infection,
luciferase activities were detected by con-
ventional assays and shown as relative light
units (RLU).
FIGURE 5. Transductional activities of
modified CRAd agents in mesothelioma
cells. 5  104 cells of mesothelioma
cells, H226 (A) and H2373 (B) were
plated on 24-well plates and infected
at a MOI of 1000 vp/cell Ad5-Survivin,
CRAd-S.RGD, CRAd-S.F5/3, or Adwt.
After 3-hour infection, the cells were
washed three times with PBS to re-
move unbound free adenoviral vectors.
The DNA was isolated from cells, and
the Ad E4 gene was determined by us-
ing RT-PCR. An internal standard, the
GAPDH gene, was used for normalizing
the DNA amount and the E4 copy
number. The ordinate is shown as E4
copies/ng DNA. The mean value  SD
of triplicate samples is shown. *p 
0.05. **p  0.01.
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cell line. These data show that the capsid modifications
enhance the viral infectivity using either CRAd agent.
Replication of Survivin-CRAds in Mesothelioma
Cell Lines
We used two CRAds, one negative control vector
(Ad-S) and one positive control (Adwt), to infect the two
tumor cell lines at 100 vp/cell in 24-well plates, as described
in Materials and Methods. The 200 l of medium was
collected from each well and spun to remove the cells from
medium. DNA was isolated from the medium, and Ad E4
copy numbers were detected by real-time PCR. The data
shown in Figure 6 compares E4 copies of Ad vectors in the
medium on days 1, 3, and 9 post-infection, as described
previously. They exhibited a similar pattern in both H226
(Figure 6A) and H2373 (Figure 6B) cell lines. The replication
ratios (calculated from the E4 copies at day 9/E4 copies at
day 1) were 1.0, 68, 417, and 3698 for Ads, CRAd-S.RGD,
CRAd-S.F5/3, and Adwt, respectively, in H226 cells; and 5.7,
507, 1703, and 11891 for Ads, CRAd-S.RGD, CRAd-S.F5/3,
and Adwt, respectively, in H2372 cells. As we expected, the
negative control, Ad-S, had no significant replication because
of its non-replicative property. Not surprisingly, the positive
(Adwt) control exhibited a higher replication rate compared
with that of two CRAd agents.
Survivin-CRAds Induce Cytotoxicity (Oncolysis)
in Mesothelioma Cells
Conventional oncolysis analysis is one of best modal-
ities for monitoring tumor cell killing. Encouraged by the
tumor-specific activity of the survivin promoter, we used
CRAd-S.RGD and CRAd-S.F5/3 as oncolytic anti-tumor
agents. The oncolytic activities of the survivin-CRAds were
evaluated for their cell-killing effect in H226, H2373,
FIGURE 6. Replication rates of modi-
fied CRAd agents in mesothelioma
cells, H226 (A) and H2373 (B). The me-
sothelioma cells (5  104 cells) were
plated on 24-well plates and infected
at a MOI of 100 vp/cell Ad5-Survivin,
CRAd-S.RGD, CRAd-S.F5/3, or Adwt.
On days 1, 3, and 9 post-infection, 200
l of medium was collected and spun
to remove the cell debris. The DNA
was isolated from the medium, and the
Ad E4 gene number was determined
by using RT-PCR.
FIGURE 7. The oncolytic effect of CRAds in me-
sothelioma and HMEC cells. 5  104 cells of either
mesothelioma or HMEC cells were plated onto 24-
well plates and infected with Ad vector (Adwt,
CRAd-S.F5/3, CRAd-S.RGD, or Ad5-Survivin) at the
indicated MOIs (100, 10, 1, 0 vp/cell). After 10-day
incubation, cells were stained with crystal violet as
described in Materials and Methods.
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BC286-2b, and MMp4 cell lines. Cytotoxicity was evaluated
after 10 days of incubation via crystal violet staining (Figure
7). Whereas the replication-incompetent Ad-S vector had no
cytotoxic effect even at 100 vp/cell, the survivin-based
CRAds induced strong cytotoxicity in all tumor cell lines
tested. Almost 100% of cells were killed even at a small dose:
1 vp/cell for CRAd-S.F5/3 in H226 and MMp4 cell lines.
CRAd-S.F5/3 had a 10-fold stronger killing effect in H226,
H2373, and MMp4 cell lines compared with that of Adwt, the
exception being BC286-2b cells, in which Adwt had a 10- to
100-fold stronger killing effect than CRAd-S.RGD.
Replication of the Survivin-CRAds In Vivo
The CRAd anti-tumor effect was analyzed in vivo using
H226 cells injected subcutaneously in an athymic mouse
xenograft model. After establishing and growing the tumor to
5 mm in diameter, 5  108 vp of Ad-S, CRAd-S.RGD,
CRAd-S.F5/3, or Adwt was injected into the tumor. After day
1 or day 7, the mice were killed, the tumors were collected,
and DNA was isolated from them. The Ad E4 copy number
was determined by real-time PCR as described. The data
shown in Figure 8 indicate that the replication rates are 45.4-,
56.9-, 0.9-, and 2838-fold for CRAd-S.RGD, CRAd-S.F5/3,
Ad-S, and Adwt, respectively The viral replication was not
seen (0.9-fold) in a non-replicative control, Ad-S, as ex-
pected. Of note, the replication-positive control, Adwt, had
much higher replication rate (2838-fold) compared with the
two CRAd agents (45.5- and 56.9-fold).
DISCUSSION
Malignant mesothelioma is an aggressive, treatment-
resistant tumor that is increasing in frequency throughout the
world. Although the main risk factor is asbestos exposure,41
simian virus 40 (SV40) could also play a role.42 Mesotheli-
oma has an unusual molecular pathology with loss of tumor
suppressor genes being the predominant theme, especially the
P16INK4A, P14ARF, and NF2genes,23–25 rather than the more
common p53 and Rb tumor suppressor genes.43,44 Median
survival remains a dismal 6 to 8 months from diagnosis.
Palliative chemotherapy is beneficial for mesothelioma pa-
tients with high performance status. The role of aggressive
surgery remains controversial, and growth factor receptor
blockade is still unproven. Gene therapy and immunotherapy
are novel strategies for treatment of mesothelioma; however,
they still are only used on an experimental basis. Some of
these approaches include adenovirus-mediated p14(ARF)
gene transfer to human mesothelioma cells,22 adenovirus-
mediated HSVtk/GCV treatment of human malignant me-
sothelioma tumors growing within the peritoneal cavity of
nude mice, with eradication of macroscopic tumor in 90% of
animals after 30 days,14,15 TSP studies (calretinin promot-
er),45 and survivin-CRAd targeted to a mesothelioma cell
line, H2373.25 Odaka et al. 46 reported that Ad-interferon beta
had a high cure rate for mice with early mesothelioma
lesions, but this decreased dramatically when tumor size
increased. However, the major challenge remains inefficient
gene delivery at both transductional and transcriptional tar-
geting levels. In this study, we sought to overcome these
limitations by using novel CRAd agents for targeting me-
sothelioma.
Replication competent adenoviruses have come into
focus as promising novel anti-tumor agents for viral oncolysis
and enhanced transfer of therapeutic genes.47,48 Tumor spec-
ificity and viral infectivity are the keys to CRAd therapy. The
former limits the viral replication in normal host cells, but not
in tumor cells; the later enhances the viral infectivity by
targeting tumor cells via a CAR-independent pathway. We
screened seven tumor-specific promoters and six capsid mod-
ifications in four mesothelioma cell lines. The mean promoter
activity of the four established cell lines was 8.9% for the
survivin promoter, 4.2% for the CXCR4 promoter, and 3.3%
for the MsLn promoter compared with that of the CMV
promoter. The mean activities of the remaining promoters
were less than 2% for the four cell lines compared with that
of the CMV promoter (Figure 2A). Bao et al.49 have de-
scribed survivin protein as being undetected in most normal
adult mouse tissues. Our data showed that the survivin pro-
moter activity was only 0.07% the activity of the CMV
promoter in mouse liver,25 and the survivin promoter exhib-
ited the lowest promoter activity (1.2% activity of the CMV
promoter) in human liver slices compared with that of other
promoters (Figure 4A). Therefore, the survivin promoter has
a tumor-on/liver-off phenotype and was chosen as a TSP to
drive Ad E1 expression in CRAd agents against mesotheli-
oma. Specifically, the liver-off status is a critical parameter
for clinical application because wt adenoviruses mainly lo-
calize to the liver when systemically administered and lead to
severe liver dysfunction.50
Adenovirus infection of cells is mediated by the attach-
ment of its capsid fiber protein to the cell surface CAR,51,52
followed by interaction of the penton base with v integrins
that triggers the internalization of these viruses.50 However,
most tumor cells express low levels of CAR, leading to poor
infection rates.53 To circumvent this problem, the develop-
FIGURE 8. Replication rates of CRAd agents in a H226 me-
sothelioma xenograft. H226 cells (2.5  106) in 200 l of
PBS were injected subcutaneously. When the tumor reached
5 mm in diameter, 5  108 vp of Ad agents were adminis-
tered (Adwt, Ad5-Survivin, CRAd-S.RGD, or CRAd-S.F5/3) by
an intratumoral injection. The mice (n  5 per group) were
killed on day 1 or day 7, and the tumors were removed.
DNA was isolated from the tumor tissues, and Ad E4 and
actin gene copy numbers were determined by using RT-PCR.
The E4 copy number was normalized as E4 copies/ng DNA.
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ment of CAR-independent Ad vectors that enhance infectiv-
ity is critical. We constructed two survivin-CRAds incorpo-
rating the capsid modification RGD or F5/3 by which the
CRAd agents target to v integrins28 or Ad3 receptors CD80/
CD86/CD4654,55 on the surfaces of tumor cells, respectively.
As regards Ad3, we have found CD46 expression to be high
in all mesothelioma lines tested, whereas CAR was low in
most lines, and CD80 and CD86 generally seemed rather low
(data not shown). Both CRAds that incorporated the capsid
modification had higher transductional activities, especially
CRAd-S.F5/3 versus the Ad5-Survivin, which contained a
native fiber with no modification (Figure 4A). Specifically,
there was a 3.3-fold and 2.2-fold increase of transductional
activity in the H226 cell line and a 3.5-fold and 2.4-fold
increase of transductional activity for CRAd-S.F5/3 and
CRAd-S.RGD, respectively, in the H2373 cell line compared
with the non-modified vector, Ad-Survivin, at 1000 vp/cell.
Survivin protein is a novel member of the inhibitor of
apoptosis (IAP) protein family, which plays an important role
in the survival of cancer cells and progression of malignan-
cies.49 Recently, the survivin gene has been described as
being selectively expressed in some of the most common
human neoplasms, including cancer of the lung,56 pancreas,57
rectum,58 brain,59 and ovary.60 In addition, the survivin pro-
tein was undetectable in normal adult mouse tissue49, al-
though trace amounts of survivin gene expression can be
detected in human organs. Our data have previously shown
that the survivin promoter has high activity in breast cancer,
ovarian cancers, and melanoma but has low activity in mouse
liver33 and human liver slices (Figure 4A). These data suggest
that the survivin promoter has a tumor-on/liver-off phenotype
and thus was a good candidate to drive the E1 gene of the
CRAd agents in this study while restricting the replication of
CRAd agents to mesothelioma cells. Furthermore, the sur-
vivin promoter is an excellent TSP to target mesothelioma
cells because: (1) The survivin gene expression (105 survivin
RNA copies/ng RNA  7.8 in H226 and 55 survivin RNA
copies/ng RNA in H2373 cells) was detected in the mesothe-
lioma cells but undetectable (0 copy) in the non-transformed
normal epithelial cell line, HMEC, which was used in this
study as a survivin-negative cell line (Figure 2C); (2) In
oncolytic analysis, the CRAd agents exhibited strong cell
killing in mesothelioma cells, especially CRAd-S.F5/3,
which has at a log lower dose than that of Adwt, the same
oncolytic activity in most of the tested cell lines, but no
oncolytic effect in the HMEC cells (Figure 7); (3) The lowest
activity was seen in the survivin promoter in human liver
slices among the seven promoters tested (Figure 4B). Thus,
the survivin promoter is an excellent TSP to restrict viral
replication in mesothelioma cells and to minimize the toxicity
to normal host cells.
Two capsid modifications, RGD and F5/3, were used in
this study to enhance the viral infectivity of CRAd agents via
a CAR-independent pathway. From transductional activity
analysis (Figure 5), all three capsid modifications do enhance
the infectivity in mesothelioma cells at an infection dose of
1000 vp/cell. The viral infectivity levels were enhanced two-
to threefold compared with non-modified Ad5-Survivin as the
control in H226 and H2373 cell lines. Specifically, the F5/3
modification had higher transductional levels than that of the
RGD-modified CRAd in mesothelioma cells. However, Adwt
had a much higher replication rate versus the two survivin-
CRAds both in vitro and in vivo (Figure 6 and Figure 8). A
possible explanation for this is that the capsid modification
enhances the viral infectivity while harming the viral repli-
cation under the study conditions, although there is no inde-
pendent evidence to verify this hypothesis. Identical results
were seen using CRAd agents targeting cholangiocarcinoma
(data not shown).
In conclusion, we identified that the human survivin
promoter is a tumor-specific regulatory element for targeting
mesothelioma. The CRAd agents armed with both the sur-
vivin promoter and a capsid modification increase tumor
specificity and viral infectivity under in vitro and in vivo
conditions. In addition, the survivin-CRAds replicate in H226
tumor cells in a murine xenograft model. The survivin pro-
moter also had extremely low activity in a non-transformed
normal epithelial cell line and in human liver tissue. The
survivin-CRAds are potentially useful for future experimental
clinical applications for human malignant mesothelioma.
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